Barrow, Hanley, Mewhinney & Strauss’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
Other funds holding DGX
FMI
DSA
Barrow, Hanley, Mewhinney & Strauss's DGX Position: Q1 2021 in Review
Barrow, Hanley, Mewhinney & Strauss sold out of Quest Diagnostics (DGX) in Q1 2021, closing a stake of 1,444 shares — an estimated $172K sold.
Barrow, Hanley, Mewhinney & Strauss first reported a position in DGX in Q1 2017 and held it in 14 quarters. The position peaked at $192K in Q3 2019. 817 funds tracked by Wall St. Rank hold DGX as of Q1 2021.
- Barrow, Hanley, Mewhinney & Strauss reported no remaining Quest Diagnostics position as of Q1 2021 after selling out during the quarter.
- Barrow, Hanley, Mewhinney & Strauss sold 1,444 Quest Diagnostics shares in Q1 2021, an estimated $172K.
- Barrow, Hanley, Mewhinney & Strauss first reported a position in Quest Diagnostics in Q1 2017 and held it in 14 quarters.
- Barrow, Hanley, Mewhinney & Strauss's Quest Diagnostics position peaked at $192K in Q3 2019.
- 817 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2021.
Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q1 2021, filed 13 May 2021.